Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not too long imo before a new 52 week high....
If Resverlogix engaged promotional IR firms then RVXCF would be the buzz of social media right now with everything going on. I'm convinced most message board posters and the like...that they're mostly industry hacks who work for these outfits...trying to stir up interest in the stocks they've been hired to promote.
Resverlogix's Apabetalone presented at Chinese Conference on Alzheimer's
https://finance.yahoo.com/news/resverlogix-presents-clinical-trials-alzheimer-120000667.html
Resverlogix Corp. (“Resverlogix” or the “Company”) (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China, this past weekend. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center
Listed on Canada's big board TSX symbol RVX.TO no listing yet in the US so it trades OTC symbol RVXCF
I think publicity is overstating things.......
If Don was on BNN talking up Apabetalone's Alzheimer's potential, along with media publications, investor videos and lots of buzz in stock based social media....if all that was happening I'd think there was a PR publicity campaign going on.
From what I've seen....and please correct me if I'm missing something...from what I have seen:
-Dr. Cummings of the Cleveland Clinic gave a presentation to a scientific conference in China about Apabetalone's potential to treat Alzheimer's.
https://www.ctad-asia.com/sites/default/files/inline-files/ASIA%20CTAD%2B%20page%20de%20couv4_0.pdf
Nothing in there about Resverlogix being a publicly traded company, the name only comes up 4 times in identifying the company as being associated with certain individuals.
-Then today we get a PR about the presentation having taken place:
https://ca.finance.yahoo.com/news/resverlogix-presents-clinical-trials-alzheimer-120000667.html
Nothing came out prior announcing the company would be attending...but thanks to Bear over on Agora investors who keep an eye on that forum already knew it was coming.
-The only thing that has a hint of publicity to it is the report put out by Zacks:
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/RVX-Apabetalone-A-Potential-Alzheimers-Play/default.aspx
Resverlogix has been paying this guy for years to cover the company, 30K a year. And quite frankly I'm convinced that the only people reading his reports are those who've already invested in RVX/RVXCF anyway. Why do they pay him $30K per yr as per the disclosure? IMO its so they can tell whiny shareholders: "look, we're trying to build shareholder value here, we're paying this guy for coverage".
And frankly I think his $5 PT is a joke....but I expect that, if things play out the way I think they will, I expect that some will hand their shares over to others in and around that price on the basis of that target being reached.
If I'm right those buying won't be basing their purchasing on some report put out by Zacks.
I don't think its "recent"........
A subset of Alzheimer's candidate patients has always been a component of BETonMACE...I think we could be heading for a Biotech Trifecta, Diabetes, Kidney and Alzheimer's.
News out on Alzheimer's presentation:
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
https://finance.yahoo.com/news/resverlogix-presents-clinical-trials-alzheimer-120000667.html
Resverlogix RVXCF attracts more investment from China....
According to filings the recent PP that took place last week involved an investor (or investors) from China. And of course Chinese Pharma giant Shenzhen Hepalink already owns about 43% of this Phase III company. For those unaware Shenzhen Hepalink is the world's biggest producer of Heparin Sodium, a blood thinner.
Rothschild & Co has been engaged to help Resverlogix, which is listed on Canada's big board Toronto Stock Exchange (symbol RVX) in seeking a listing on a US exchange. Because Resverlogix isn't listed on an American exchange its shares trade OTC in the states.
I can't imagine a company of Rothschild & Co's stature would take on a small Canadian biotech as a client unless there was huge potential...
Phase III trial results are due in and around 6 months time...its an event based trial that is attempting to prove that the company's lead compound Apabetalone will reduce the time to a Major Adverse Cardiac Event (MACE) in patients with Diabetes Mellitus (full blown insulin dependent) who are at extreme high risk of an event like a stroke or heart attack.
The trial will conclude after 250 such MAC events. If the results confirm what was seen in earlier Phase II trials, then I see Apapbetalone as having billion dollar potential and for Resverlogix to soar to a valuation in the billions.
Another tout sheet recommendation...
Great at bringing in the sheep....sign up for their free email blasts to know what they're pumping.
One of the biggest risks here is lack of finance....
I still think the single biggest risk is that of trial failure...but without the do re mi to get to the finish line Apabetalone can't achieve either success or failure.
I've done a fair bit of reading on success rates for drug trials and it seems the biggest drop off is in ph II with only something like 35% or so of drugs advancing to phase III. Then success in phase III is something close to 60% but those numbers are dragged down by cancer drugs which apparently have a much higher failure rate. Get to an NDA and the numbers I'm seeing suggest 90% approval.
Interestingly RVXCF traded higher at the opening while RVX went down....
I think we're going to be seeing lots more news in the coming weeks.
Who's heard of Epigenetics and BET Inhibition?
Newer area of the biotech space and one early mover is way out in front, Resverlogix with a drug named Apabetalone nearing the end of a Phase III event based trial for patients with Diabetes Mellitus as well as subsets of patients on dialysis (Chronic Kidney Disease) and reduced Cognitive function, (Alzheimer's).
This has blockbuster written all over it, but very the company is very quiet. No promoters or IR consultant types hyping it.
I guess they figure they don't need it. Here's a SA blog post I did.
https://seekingalpha.com/instablog/15663412-joe_retail/5205099-apabetalone-billion-dollar-blockbuster-making
Mostly just bragging
Its been viewed about 300 times, that 9 monthish chart shows the benefits of patience....if the PPS preforms as well over the next 9 months as it did over the last 9 we'll be looking at RVXCF trading up around $5...I still think that's incredibly low, but another 100+% climb would still be nice.
Another Seeking Alpha Write up...
https://seekingalpha.com/instablog/15663412-joe_retail/5204850-bulls-bears-slug-vuzix-vuzi
Did a post on Seeking Alpha....
It compares Vuzix with another company and shows what bullish news, hype and promotion can do for a stock versus being quiet and letting results speak for themselves:
https://seekingalpha.com/instablog/15663412-joe_retail/5203761-glowpoint-and-vuzix-study-contrasts-similarities
Confirmation bias
Its not out of the ordinary for a shareholder to believe the shares he's holding, that they're worth exponentially more than they're currently trading at.
Of course we had the naked shorting and forced covering earlier this summer which for me pretty much confirmed the fact that RVX was being heavily manipulated. But even though the house 100 forced buy ins to satisfy delivery failures, even though there hasn't been any for a while now...after seeing over 1 million shores that were naked short sold...I think its fair to assume the fun and games haven't stopped.
I still don't have the voting info for the shares held in my margin account, although I have received the material for a registered account. I take that to mean my margin account shares have been loaned out and resold, so the voting rights attached to those shares are with whomever bought them from the short seller.
Quite honestly I think the money is there now....
And I think the reason the move up stalled is because someone or someones put their foot down on the PPS. I believe the problem is that there are plenty of buyers, but not enough sellers willing to part with their shares for even $3 or $4 CDN.
The problem is that if RVX.TO goes to $5, $6 and starts climbing...that kind of move will attract attention and lead to even more buying in a stock that I already believe has a serious liquidity problem.
Short interest update Monday after the bell should be out and unmuddy the waters at least a little bit.
This is simply my take...
Ultimately money can overcome almost any obstacle, but Hepalink's position, and to a certain extent that of Eastern (they're around 20% I believe)...I think it complicates issues, plus you have Royalty Preferred Shares held by Zenith. I believe it would make Resverlogix and/or just Apabetalone a very convoluted acquisition.
It should be noted, in case you're not aware...Eastern Capital, that's actually Kenneth Dart of the Dart Container fortune, he has a net worth estimated at over $6 billion. Eastern is simply his investment company.
I've long considered the most likely deal to be one where Shenzhen Hepalink takes Resverlogix over and maybe even uses an acquisition as an entry to the North American capital markets. Still, even while I think its 'most likely' I also see the share structure and ownership situation to be more than a little problematic, but just a bit less so if Hepa was doing the acquiring.
I think tomorrow is gonna be fun...
Short interest was over 800K as per stockwatch up to July 31st. The next update should be out on the 20th after the bell and it will have the number up to August 15th...up to tomorrow in other words.
Just a hunch on my part but I'm thinking those caught short will want that number whittled down as much as possible for when it becomes public.
Resverlogix engages Rothschild & Co in seeking US listing...
Yes, THAT Rothschild....chairman is Alexandre de Rothschild. Resverlogix is about 43% owned my major Chinese Pharma Co Shenzhen Hepalink, the world's largest supplier of Heparin Sodium, a blood thinner.
I think something bigger than just a US listing could be brewing. Resverlogix trades on Canada's main exchange the TSX under the symbol RVX, in the US it trades OTC with the symbol RVXCF.
Too quiet here for too long....
I think we're going to start seeing closing prices in the 20s this week. And if news comes out about microlearning and includes a blockchain angle...then I think it could be Katie Bar the Door time.
Hey Cabel...
The post noretreat referenced is at agoracom.com in the resverlogix forum, posted june 21 if memory serves by a user with the name tundup (going off memory here).
As for your belief that $20 is doable, I agree...although I'm thinking $10 by EOY has a good chance, with $20 sometime next year if everything goes right.
There's so much that can happen though...even if the trial achieves great results in primary and secondary outcomes....there's the business side.
Resverlogix just engaged Rothschild & Co with respect to seeking a US listing. I've seen other CDN companies get listings on the NAZ, Stellar Biotech springs immediately to mind...and they didn't engage an advisor of the stature of Rothschild. In point of fact I don't think they engaged any advisors with respect to their uplisting. They did hire some outfit called Huft or something like that for corporate communications (IR promo imo).
It has me thinking there may be something bigger in the cards than a simple listing on the Nasdaq.
Chinese Pharma Co Shenzhen Hepalink owns something like 43% of Resverlogix already, they're the world's largest producer of Heparin Sodium according to the independent analyst report put out by Beacon's Dr. David Kideckle, a man who by the way has both a PHD in neursciences AND an MBA if memory serves.
Hepalink is a publicly traded company, but only in China on the Shenzhen stock exchange. I can't help but speculate that there may be M&A type discussions going on that would result in Hepalink using its large ownership position to gain entry to the US market....
Fun times in any case, I can see a variety of ways things could play out, ways that are all positive for shareholders.
I have, $8.55 PT for RVX.TO
That would be about $6.50 in USD, it was a 12 month target price, and it came out November last year, so we're getting close. I'm going off memory because the link I had for the PDF no longer works.
But as I recall what most impressed Dr Kideckle (sp?) was the complement cascade potential for Apabetalone. The way I understand it is this...
Think of a multi-tiered waterfall, where the water descends into a pool and then descends again...and again and again. There's a waterfall near Quebec City called "Les 7 Chutes"....7 waterfalls. There's a good pic of it here:
https://www.dreamstime.com/royalty-free-stock-images-waterfalls-les-sept-chutes-image8931249
So the way I understand it is this...the plaque, calcificaton, cholesterol and associated "gunk" (that's the official medical term eh) that build up in our arteries, it spills over and can cause conditions like Diabetes, in turn Diabetes can lead to Kidney failure, in turn that can lead to increased risk of cardio vascular disease...and other conditions like thrombosis, alzheimers...degenerative diseases affecting the nervous system, retinas....
Like the cascading waterfall it just keeps causing problems..
Growing losses....
Not healthy, but thanks to the promotional pump up to $10+ and the dumping of shares they have a decent balance sheet...about 12 months worth of cash before they're out of money again at this rate.
If they shutter the business and fire everyone they could make $1+ million per year on the $30 or so million they have left if they could get a return of 4%.
I know the company is working with payer groups....
Go to page 21 of this Feb/2018 PPP:
https://www.resverlogix.com/upload/event/29/71932314d948/rvx-bio-ceo-presentation-2018.pdf
They have a deal with Hepalink for China...
China and the "Territories" which I believe includes places like Taiwan. Then the deal with Medison in Israel, that is correct.
They also have a deal with Hepalink USA, (the American subsid of Shenzhen Hepalink) which gives them the right of first refusal (ROFR) for the licensing the US market.
Yesterday on the Pinks...
It went up to $2.92 and then closed at $2.50 for a nice gain on the day.....today it got as high as $2.90 and closed for another nice gain on the day at $2.66
What will happen tomorrow? I don't know, my crystal cracked a long time ago...but long term I think we're golden.
The warrants are the better deal right now imo...
They're trading today for about $2 CDN, which means that RVX.TO would need to get over $4.05 for conversion to make sense...about a 10% increase from where its trading today.
I had a market order in last week for more warrants and I only got a partial fill, I think they're very illiquid right now with MMs caught between a rock and a hard place.
I'm not 100% current on them...
But I believe they would need to have a stronger balance sheet and imo targetting $5+ per share is more realistic...in fact I would aim for $10 if I were them.
The vote to give management authorization to effect a consolidation at their discretion is still over a month away and the way things are moving I think it may become a moot point.
Personally my opinion is that Resverlogix should have a market capitalization of $1 billion USD minimum....and I believe that is being incredibly conservative. Right now its still below $500 million USD....
And with Apabetalone's blockbuster potential I don't think a pipeline value of double or even triple that number is unrealistic.
I wrote this blog post in Dec about RVX.WT
Here:
http://avoidthebag.blogspot.com/2017/12/bullish-on-resverlogix-you-may-want-to.html
I wonder if there's more to it....
Engaging a company of Rothschild and Co's stature to advise on seeking a US listing...it strikes me as over kill. Like hiring F. Lee Bailey as a lawyer for traffic court and a parking ticket.
Shenzhen Hepalink (over 40% ownership stake) recently filed about a bond issue in China...I'm wondering if there might be a deal in the works for some M&A type deal to get them a US listing....
$RVXCF too bad nobody was talking about this one in May...
Oh wait, I was
How 'bout a video on RVXCF?
Been breaking out since start of June and volume still light...blockbuster drug, Rothschild and Co engaged as an advisor for the seeking of a US listing (no more crappy OTC), investment by Chinese Pharma Hepalink, the world's largest producer of blood thinner Heparin.
This looks like the real deal and this stock could go to the $100s in the years to come imo...
Rothschild & Co advising obscure CDN Biotech NEWS!!!
https://finance.yahoo.com/news/resverlogix-intends-pursue-u-listing-210000692.html
Its looking more and more like Phase III drug Apabetalone could be the real deal, I see BLOCKBUSTER POTENTIAL.
Rothschild & Co advising obscure CDN Biotech (news)
https://finance.yahoo.com/news/resverlogix-intends-pursue-u-listing-210000692.html
Looking more and more like Phase III drug Apabetalone is the real deal, this could be a BLOCKBUSTER!!!
$RVXCF maybe $3 tomorrow?
Phase III tor line data due out around EOY...success and I am gonna be rich!!!
$RVXCF Watch the close, hit another 52 wk high today....
MMs are pinched with Canadian markets closed. OTC garbage companies don't get advised by firms as prestigious as Rothschild & Co....imo this has MONSTER written all over it.
Here's a blog post I did back in June:
http://avoidthebag.blogspot.com/2018/06/resverlogix-naked-story-fully-annotated.html
Imagine that....
Align research, another IR promotional firm touting Vuzix. Are there any left they haven't used?
http://www.alignresearch.co.uk/our-services/
Nice Start on the OTC for RVXCF....
I can't imagine MMs have much or any to sell though, which imo means they're gonna have to go short to satisfy buyers.
$RVXCF - PUT IT ON YOUR RADAR FOR MONDAY!!!
This one has already made a nice jump this summer, going from about $0.90 cents at the end of May to its current $2.50, but this could be JUST THE START.
The company is a biotech with an epigenetic compound (drug) named Apabetalone in a phase III trial that's slated to be completed around the end of this year.
They just announced last week they're going to be seeking a US listing, and that would be fantastic because it would get the stock off the crappy OTC Pink sheets in the US where it trades now. In Canada Resverlogix trades under the symbol RVX on Toronto's big board TSX.
Even bigger is the fact that they have Rothschild & Co who are advising them about seeking a US listing. YES THAT ROTHSCHILD, oldest of the old money families and a favorite topic of conspiracy theorists.
Do some research....I offer up a blog post I wrote in June as a starting point.
http://avoidthebag.blogspot.com/2018/06/resverlogix-naked-story-fully-annotated.html
If Apabetalone succeeds in treating Diabetics and all the other potential diseases with arterial components, like Kidney, Alzheimers, Thrombosis, Fabry, Degenerative Retinal, HIV....its too long a list.
This could end up being worth $100+ in a few years imo.
Holiday Monday in Canada, no TSX trading.....
Any thoughts on what's in store for the OTCBB and RVXCF tomorrow? Will last week's increased volumes and higher prices continue, or maybe will things cool off while the TSX, where most of the trading takes place, is closed?
I'm hoping we see at least 100K trading.